UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program
UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears [...]
Charles River Labs deals with SAMDI Tech to boost discovery business
Charles River Labs deals with SAMDI Tech to boost discovery [...]
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug
Yet another delay at Amryt as EMA calls in experts [...]
Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials
Homology scratches cash itch with manufacturing deal, bagging $130M to [...]
Taysha mulls tweaks to gene therapy trial after subject dies
Taysha mulls tweaks to gene therapy trial after subject dies [...]
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial
Neck and neck with Pfizer, Moderna gives first dose of [...]
9-year J&J science chief Stoffels to steer Galapagos’ rebound as CEO
9-year J&J science chief Stoffels to steer Galapagos’ rebound as [...]
Septerna emerges with $100M to spark ‘second golden age’ of prolific drug target GPCR with pioneer as co-founder
Septerna emerges with $100M to spark ‘second golden age’ of [...]
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit
Incyte pulls FDA filing for cancer drug approval over confirmatory [...]
Gilead’s $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47
Gilead’s $4.9B oncology bet hit with partial clinical hold, forcing [...]